BioSpace News Archive

July 16, 2019 08:00 AM Eastern Daylight Time--Tishman Speyer, one of the world’s leading developers, owners, operators and asset managers of first-class real estate, and Bellco Capital (“Bellco”), an investment firm founded by biotechnology entrepreneurs Drs. Rebecka and Arie Belldegrun, have formed Breakthrough Properties (“Breakthrough”).

Females with bladder cancer are more likely than their male counterparts to experience a greater number of symptoms and challenges with coping, less support and, as a result, lower perceptions of quality of life.

LC GC®, a leading multimedia platform of peer-reviewed technical information on the field of chromatography and the separation sciences, will present the webcast “A Practical Guide to Analytical Method Development” Thursday, July 18, at 2 p.m. EDT.

Candela Corporation, Lumenis Ltd., a global leader in the field of minimally-invasive clinical solutions for the aesthetic, surgical, and ophthalmic markets, and its subsidiary, Pollogen Ltd., announce that they have entered into a mutual settlement agreement and sublicense ending the patent disputes between the companies.

Issues related to claims reconciliation emerge as a pain point for owners of independent pharmacies as they manage their business.

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the upcoming International Society for Thrombosis and Hemostasis(ISTH) meeting being held in Melbourne, Australia from July 6-10, 2019.

Catalyst Biosciences, Inc.(NASDAQ: CBIO), and Mosaic Biosciences today announced the presentation of new data on pegylated CB 2782 (CB 2782-PEG), Catalyst’s preclinical anti-C3 candidate being developed for the treatment of geographic atrophy (GA) associated dry age-related macular degeneration (dry AMD) at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Vancouver, British Columbia, from April 28 - May 2, 2019.

Catalyst Biosciences, Inc., Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Needham & Company 18th Annual Healthcare Conference at 12:50 p.m. EDT on Tuesday, April 9, 2019 at the Westin Grand Central Hotel in New York.

Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that the European Commission has awarded orphan designation of its Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for the treatment of haemophilia B (with or without inhibitors).

Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the presentation of a poster, in collaboration with partner Mosaic Biosciences, at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Vancouver, British Columbia, from April 28-May 2, 2019.